



Paxlovid (nirmatrelvir and ritonavir)

Purpose: For the treatment of mild to moderate COVID-19, patients must have tested positive for COVID-19 and are at high risk of progression to hospitalization and/or death (ie. elderly age, high risk conditions, and/or weakened immune system). This is not for pre- or post- exposure. Treatment should be initiated within 5 days of symptom onset.

Age and Weight Requirement: 12 years and older and at least 88 lbs

Dosing and Administration: Take one tablet of ritonavir (100 mg) and two tablets of nirmatrelvir (150 mg each) by mouth twice daily for 5 days.

Side Effects: Altered sense of taste, diarrhea, high blood pressure, muscle aches

Efficacy: The relative risk reduction for PAXLOVID compared to placebo was 88% (95% CI: 75%, 94%).

Clinical Pearls

- Prescription should specify numeric dose of each active ingredient within Paxlovid
- Renal dose adjustments:
 - eGFR 30-60 ml/min: Take one tablet of ritonavir (100mg) with one tablet of nirmatrelvir (150 mg) by mouth twice daily for 5 days.
 - eGFR less than 30 ml/min: Not recommended
- Hepatic Dose adjustments:
 - Not recommended with severe hepatic impairment (Child-Pugh Class C)
- Patients using combined hormonal contraceptives should use an effective alternative contraception method or an additional barrier method.
- There are significant drug interactions with Paxlovid as it is a CYP3A4 inhibitor. Please review the patient's medication list. Interacting medications could have increased serum concentrations and dangerous adverse effects.
- Do not chew, crush, or break tablets
- If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.

At this point in time, supply is extremely limited, so prescriptions for oral COVID-19 treatment will not be filled until we speak to the patient/caregiver to confirm eligibility. Patients will be called in the order in which prescriptions are received and oral therapeutics will be filled in the order in which we speak to patients. All patients will be provided with a copy of the Patient EUA Fact Sheet, and every course will be tagged "Do not dispense after XX date" to prevent dispensing outside of the 5-day treatment window. We will enforce **contactless** dispensing of COVID therapeutics, so please ask your patients to remain outside of the pharmacy and to call us if they have any questions.

Thank you for your partnership with Moose Pharmacy!

Please call us with any questions and feel free to fax prescriptions using the provided template on the next page.



P: (704) 436-9613 F: (704)436-6512